Current opinion in oncology · 2026
Upper tract urothelial carcinoma associated with Lynch syndrome.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chelluri R, Kovell S, Montanaro F, Chandran E, Banday A Rouf, Gurram Sandeep, Apolo Andrea B
Аннотация
PURPOSE OF REVIEW: This review outlines the molecular biology, diagnostic tools, screening strategies, and management options of Lynch syndrome (LS)-associated upper tract urothelial carcinoma (LS-UTUC).
RECENT FINDINGS: LS is an autosomal dominant disease characterized by faulty mismatch repair during DNA replication. This manifests as an increased risk of developing LS-UTUC. Novel insights into oncogenesis, the role of upfront germline testing, and management are described.
SUMMARY: Clinicians should be aware of the increased risk of developing UTUC in a patient who has LS. Conversely, clinicians should consider LS in patients who present with de novo UTUC. Clinical and molecular tools exist to aid in the diagnosis; the role of germline testing is evolving.
RECENT FINDINGS: LS is an autosomal dominant disease characterized by faulty mismatch repair during DNA replication. This manifests as an increased risk of developing LS-UTUC. Novel insights into oncogenesis, the role of upfront germline testing, and management are described.
SUMMARY: Clinicians should be aware of the increased risk of developing UTUC in a patient who has LS. Conversely, clinicians should consider LS in patients who present with de novo UTUC. Clinical and molecular tools exist to aid in the diagnosis; the role of germline testing is evolving.